Skip to main content
Fig. 5 | Clinical Proteomics

Fig. 5

From: Proteomics of AML1/ETO Target Proteins: AML1–ETO Targets a C/EBP–NM23 Pathway

Fig. 5

AML1–ETO blocks the C/EBP protein-mediated NM23 inhibition: Human kidney 293T cells were transfected with 0.2 μg NM23h1-luc promoter (provided by Dr. Dirk Eick, GSF, Munich), 0.1 μg C/EBPα (a), or 0.1 μg C/EBPβ (b) or 0.1 μg C/EBPδ (c) [30], and 0.2 μg AML1–ETO [21]. d EMSA analysis using radiolabeled probe and 6 μg of in vitro translated C/EBPα (left panel) showing binding of C/EBPα on GCSF receptor promoter served as positive control; subsequently, binding of human NM23 promoter was observed with same ivt C/EBPα. Results are representative of three separate experiments

Back to article page